Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sera from cancer patients specifically suppressed phosphofructokinase (fructose-6-phosphate kinase [PFK], EC 2.7.1.11), a rate-limiting enzyme in the glycolysis pathway. Among 418 cancerous sera, 68.7% evidence suppression; there was no organ specificity. Among 42 sera from early gastric cancer patients, 29 (69.0%) were positive, as were advanced gastric cancer, 14/19 (73.3%) pancreas cancer, and 75/101 (74.3%) lung cancer sera. In contrast 6/50 (12.0%) sera from patients with gastroduodenal ulcer, 3/23 (13.0%) with myoma uteri, and 0/6 with lung tuberculosis were positive. Patients with diabetes mellitus and those receiving steroid hormone therapy showed strong positive suppression. Comparative studies using other tumor markers (immunosuppressive acid protein, carcinoembryonic antigen, alpha-fetoprotein, beta 2-microglobulin, and ferritin) and the same sera used from PFK assay showed that the PFK method was two to three times more sensitive. Sephadex G-200 column chromatography revealed that the PFK-suppressive activity was retained in the postalbumin fraction. The PFK method may represent a promising new cancer screening method.
 ...
PMID:A new cancer marker: a possible cancer screening method based on the suppression of phosphofructokinase by sera from cancer patients. 293 46

The hypothesis that somatostatin, a compound with antitrophic effects on the gastrointestinal tract, may affect beneficially the progression of advanced intestinal cancer has been tested in a small pilot study. Ten patients, four with advanced pancreatic cancer, four with advanced colorectal cancer and two with gastric cancer, were treated with a long-acting analogue of somatostatin, SMS 201-995, 50, 100 micrograms subcutaneously twice daily. There were no clinical, radiological or biochemical indicators of a response to this treatment. There are no indications from this study that hormonal manipulation alters the rate of growth of advanced gastrointestinal cancer.
 ...
PMID:SMS 201-995 treatment and advanced intestinal cancer: a pilot study. 297 16

Epirubicin (4'-epidoxorubicin) is an antineoplastic agent derived from doxorubicin. The compounds differ in the configuration of the hydroxyl group at the 4' position. Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle. Epirubicin is administered by intravenous (IV) injection. It is metabolized by the liver and primarily eliminated in the bile. About 10% of the drug is eliminated in the urine. Dosage adjustments are recommended for patients with liver metastases or elevated liver function tests. The elimination half-life of epirubicin is 30 to 40 hours. Clinical studies indicate activity in breast cancer, non-Hodgkin's lymphomas, ovarian cancer, soft-tissue sarcomas, and pancreatic cancer. There is also evidence of activity against gastric cancer, small-cell lung cancer, and acute leukemia. Epirubicin has limited activity as a single agent against head and neck tumors or non-small-cell lung cancer, but may be beneficial in combination with other agents. The overall activity of epirubicin appears to be comparable with that of doxorubicin. However, more studies are needed to define its role in combination chemotherapeutic regimens. The acute dose-limiting toxicity of epirubicin is myelosuppression. Nausea, vomiting, and alopecia are also common. Epirubicin may cause transient cardiac arrhythmias and alterations of the electrocardiogram. Chronic therapy is limited, but available data indicate that epirubicin can be administered in higher cumulative doses than doxorubicin before cardiotoxicity limits further therapy.
 ...
PMID:Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. 300 21

In a group of 76 patients with various gastrointestinal malignant lesions, we found that peritoneal washings contained tumor cells in 43% of patients with gastric cancer, 22% of those with pancreatic cancer, and 3% of those with colonic cancer. Aside from tumor site, we were unable to identify any criteria that would help to predict the presence of malignant cells in peritoneal fluid specimens. We found no malignant cells on cytology in patients with early localized cancer. The ease of obtaining such data, coupled with the fact that the test is inexpensive, makes cytologic assessment attractive. Furthermore, the results of cytology have been shown to bear a direct relationship to prognosis in some cancers and may serve as an indication for more intensive therapy. The results of sequential cytology tend to support the theory that tumor manipulation may be a source of intraperitoneal spread in certain tumors.
 ...
PMID:Abdominal fluid cytology in patients with gastrointestinal malignant lesions. 301 16

A review of the activity of epirubicin in advanced gastrointestinal tumors is presented. In gastric cancer epirubicin has comparable activity to its parent compound doxorubicin with less toxicity. Epirubicin seems particularly active in pancreatic cancer as shown by the results of two EORTC Gastrointestinal Group studies. In advanced colorectal cancer results of different studies are conflicting and the drug may have limited activity in rectosigmoid cancer.
 ...
PMID:Epirubicin in advanced gastrointestinal (GI) cancer. 301 49

This clinical study was undertaken in order to evaluate the effect of CDDP on 43 patients with far-advanced or recurrent carcinoma of the gastrointestinal tract. For all these patients, CDDP at 100 mg/m2 had been administered by continuous intravenous infusion for 24 hours and repeated one to seven times at an interval of 3 to 4 weeks. The effect of this therapy was assessed according to the criteria of clinical evaluation of chemotherapy for solid cancers by Koyama and Saito. The response rate for both complete and partial response was 27.9% among all 43 patients, including 47.1% (8/17) for gastric cancer, 33.3% (1/3) for esophageal cancer, 25.0% (1/4) for hepatocellular carcinoma, 25.0% (1/4) for carcinoma of the gallbladder or bile duct, 20.0% (1/5) for pancreatic cancer and none (0/10) for colorectal cancer. In particular, a good response rate of 37.5% (3/8) was obtained for patients with recurrent tumor and one of 33.3% (6/18) for those with palliative resection of the primary tumor, which was much higher that the rate of 17.6% (3/17) for those without resection. As for the side effects of CDDP therapy, gastrointestinal symptoms were most frequently found in 78.3% of patients followed by bone marrow suppression in 15.2%, and abnormalities of hepatic and renal function in 4.3% and 4.3%, respectively. Consequently, 24-hour continuous intravenous infusion of CDDP was considered to be effective for far-advanced or recurrent carcinoma, especially in cases of gastric cancer.
 ...
PMID:[Clinical study on the effect of 24-hour continuous intravenous infusion of CDDP in far-advanced and recurrent carcinoma of the gastrointestinal tract]. 303 10

A sandwich enzyme immunoassay was established to measure an adenocarcinoma-associated antigen (antigen YH206) detected by monoclonal antibody YH206. Levels of antigen YH206 exceeding the cut-off value (25 U/ml) were found in the following percentages of 163 patients with various cancers: stomach cancer 37.2%, colon cancer 14.8%, pancreas cancer 43.3%, common bile duct cancer 28.6%. In contrast, only one out of 33 (3.0%) healthy donors and 7 of 104 (6.7%) patients with benign diseases had slightly elevated levels of the antigen. As regards the relationship between antigen YH206 levels and clinical stages, abnormally high levels of the antigen were found in the following percentages of 29 patients with stomach cancer: stage I 16.7%, II 0%, III 42.9% and IV 54.5%. Serial monitoring of antigen YH206 in two patients with cancer revealed that the level of the antigen increased as the disease progressed. It was also found that perchloric acid treatment of serum might be useful to decrease any false-positive reactions.
 ...
PMID:A sandwich enzyme immunoassay of an adenocarcinoma-associated antigen, YH206, in cancer sera. 303 13

The array of tumor-associated antigens has been extended recently by introducing novel mucin-like antigens, i.e. CA19-9, CA50, DU-PAN-2, TAG72/CA72-4 to gastroenterological oncology. Particularly in pancreatic cancer preoperative staging, postoperative prognosis, and follow-up have been improved considerably by determinations of these new tumormarkers. Yet, despite their irrelevance to screening procedures they may contribute to the differential diagnosis between benign and neoplastic pancreatic diseases ruling out false positive results by serial determinations. In contrast in colorectal cancer CEA is still superior to the tumor markers mentioned. Whether all of these tumormarkers indeed represent a diagnostic progress especially for tumors with no marker available like gastric cancer still has to be determined.
 ...
PMID:[Immunologically defined tumor-associated antigens: the possibilities and limitations of their use in gastroenterology]. 306 30

Based upon literature data, a 2-fold risk for gastric and colorectal cancer and a 2- to 5-fold risk for pancreatic cancer are predicted after remote peptic ulcer surgery. The association between previous ulcer surgery and subsequent gastric cancer appears firm; the linkage between colorectal and pancreatic cancer is more tenuous. Increased formation of carcinogens in the hypochlorhydric stomach following gastric surgery may be incriminated. Other conditions have features in common with the operated stomach and are also thought to be a suitable microenvironment for the subsequent development of cancers. Viewed in that light, further research of the putative relationship between peptic ulcer surgery and carcinogenesis and their underlying mechanism is highly desirable. Molecular cancer epidemiology and environmental pathology are proposed as useful tools for such studies. In the long run, the hypochlorhydric stomach might be a condition suitable for the chemoprevention of cancer.
 ...
PMID:Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism. 307 May 56

The combined effect of human interferons and chemotherapeutic agents on human gastric cancer cell lines and a human pancreatic cancer cell line was studied in vitro. Interferons, when used as a single drug, showed inhibitory effects in the order, gamma greater than beta greater than alpha. However, there was no significant difference between the effects of natural and recombinant interferon. In combination therapy, the chemotherapeutic agents should be administered first, followed by administration of interferon(s), since this method showed the most inhibitory effect. Low concentration of 5-FU (0.001-0.01 microgram/ml) or methotrexate (0.01-1 microgram/ml) was able to inhibit the growth of cell lines when combined with interferon. These results suggested that in clinical use, low amounts of chemotherapeutic agents followed by administration of interferon(s) could be available with minimum side effects and with more pronounced anticancer effects.
 ...
PMID:[Antitumor effect of interferons with chemotherapeutic agents]. 308 Sep 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>